Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). The SELECT trial demonstrated a 20 percent reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease without diabetes. Longevity-relevant mechanisms include sustained weight loss, improved insulin sensitivity, lower inflammation, and possible cognitive and renal protection. Off-label use solely for lifespan extension in healthy adults is investigational and not endorsed.